RxDoctor Payments Data

Kyle Rapp, MD

Family Medicine · Mount Vernon, INNPI 1336101682

Payments from drug & device makers

$6,655in general payments, 2019–2025

Across 476 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$596
  • Amgen$549
  • Merck$483
  • Boehringer Ingelheim$365
  • Otsuka America Pharmaceutical, Inc.$333
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,53098%
  • Education$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,655 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$102,264
Medicare patients
370
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$82,144
JardianceEmpagliflozin75$71,750
FarxigaDapagliflozin Propanediol71$56,649
OzempicSemaglutide48$55,026
MounjaroTirzepatide33$38,930
Janumet XrSitagliptin Phos/Metformin Hcl22$30,688
JanuviaSitagliptin Phosphate18$27,618
TrulicityDulaglutide17$27,097
EntrestoSacubitril/Valsartan29$24,766
XareltoRivaroxaban22$24,143
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$23,105
Tresiba Flextouch U-200Insulin Degludec37$21,531
Synjardy XrEmpagliflozin/Metformin Hcl20$18,753
RybelsusSemaglutide16$17,236
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$13,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta$365$110,659138 claims
PfizerEliquis, Abrysvo, Paxlovid$284$95,446159 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$143$85,097114 claims
Novo NordiskOzempic, Rybelsus$596$72,26264 claims
MerckJanumet Xr, Januvia, Belsomra$483$70,64369 claims
Lilly USA, LLCMounjaro, Trulicity$232$66,02750 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$303$31,63783 claims
NovartisEntresto$95$24,76629 claims
Johnson & JohnsonXarelto$68$24,14322 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$151$10,12119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Mount Vernon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →